New drug combo tested for Tough-to-Treat stomach cancer
NCT ID NCT07364422
Summary
This study is testing a new drug combination for people with advanced stomach cancer that has returned or spread after at least two prior treatments. Researchers want to find a safe dose and see if the combination of JPI-547 and irinotecan can shrink tumors. The trial will enroll about 49 patients to check for side effects and measure how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.